Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting Luoxis Diagnostics Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) ENGLEWOOD, Colo., Aug. 19, 2014 /PRNewswire/ -- Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced an upcoming presentation at the 73rd Annual Meeting of the American Academy of Surgical Trauma (AAST) and Clinical Congress of Acute Care Surgery in Philadelphia, Pennsylvania that will be held September 10-13, 2014. The presentation will report results from a recently completed five-year prospective clinical trial conducted using Luoxis proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic platform to assess prognosis and outcomes in patients with traumatic brain injury. This multi-center study on traumatic brain injury was conducted by Luoxis research partner Trauma Research, LLC in collaboration with Swedish Medical Center in Englewood, Colorado, Saint Anthony Hospital in Lakewood, Colorado, Centura Health System in Denver, Colorado, and the Medical Center of Plano in Plano, Texas. The presentation at AAST, titled Significant Differences in Oxidative Stress between Healthy Controls and TBI Patients: A 5-Year Multicenter Prospective Observational Study Cohort Study, will be presented on September 10th beginning at 5:30 PM in Franklin Hall B at the Philadelphia Marriott Downtown. About the RedoxSYS Diagnostic SystemThe RedoxSYS Diagnostic System is a first-in-class clinical diagnostic platform that measures oxidation-reduction potential (ORP) in the body, a homeostatic measurement of oxidative stress that changes in response to injury or illness. The result of nearly two decades of clinical, scientific and technical R&D, the RedoxSYS System is able to provide the only complete assessment of a patients oxidative status, which has broad diagnostic application across multiple disease areas where oxidative stress is implicated. Luoxis is currently developing RedoxSYS as a simple, rapid blood test for use in the critical care setting, where its ability to provide an objective measurement of patient illness and predict potential complications may enable physicians to improve resource allocation and align higher levels of care with the most critically injured and ill patients, leading to improved outcomes and optimal workflows. About Luoxis DiagnosticsLuoxis Diagnostics is an in vitro diagnostics company focused on developing and commercializing its proprietary, CE Marked RedoxSYS Diagnostic System. The company is currently developing RedoxSYS to address the $4+ billion critical care market, where it has the potential to provide hospitals with a single, rapid solution with unmatched diagnostic/prognostic value for conditions with significant medical need, and for which few diagnostic biomarkers exist. Luoxis is conducting initial market development for RedoxSYS in select European territories in order to validate and quantify the clinical value of RedoxSYS for monitoring injury severity and patient oxidative stress following traumatic brain injury, multi-trauma injury, and other critical illnesses. Luoxis is also pursuing U.S. regulatory clearance for RedoxSYS, based on completed and ongoing clinical studies in multiple critical care conditions in the United States, including TBI, multi-trauma injury, stroke, sepsis, and other life-threatening conditions. Luoxis has research collaborations in place with leading centers around the world. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc. For more information, visit luoxis. About Ampio PharmaceuticalsAmpio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. RedoxSYS and Luoxis are trademarks of Luoxis Diagnostics, Inc. Forward Looking StatementAmpios statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as believe, expect, plan, anticipate, and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampios filings with the Securities and Exchange Commission, including Ampios Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. For Investors & Media:Tiberend Strategic Advisors, Inc. Joshua Drumm, Ph.D.jdrumm@tiberend; (212) 375-2664 Amy Wheelerawheeler@tiberend; (646) 362-5750 Logo - photos.prnewswire/prnh/20130718/MM49747LOGO SOURCE Luoxis Diagnostics, Inc. RELATED LINKSluoxis
Posted on: Tue, 19 Aug 2014 12:31:33 +0000
Trending Topics
Recently Viewed Topics
© 2015